Auto Draft

Merck & Co., Inc. (NYSE:MRK) is included among the 12 High Dividend Stocks Picked by Billionaire Ray Dalio.

Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV

On April 17, Merck & Co., Inc. (NYSE:MRK) announced that the European Commission (EC) has approved ENFLONSIA (clesrovimab) to help prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.

ENFLONSIA should not be used in infants who are hypersensitive to the active substance or any of its excipients. The treatment is a preventive, long-acting monoclonal antibody. It is designed to offer direct and fast protection that lasts up to five months, which typically covers a full RSV season. It also uses a non-weight-based dosing approach.

With this approval, ENFLONSIA can now be marketed across all 27 European Union member states, along with Iceland, Liechtenstein, and Norway. Availability will differ from country to country and will depend on factors such as reimbursement timelines. ENFLONSIA has already been approved in the United States, Canada, Switzerland, and several other markets for use in infants during their first RSV season. The company is continuing to seek approvals in additional countries.

Dr. Macaya Douoguih, vice president, Therapeutic Area Head, Global Clinical Development, Merck Research Laboratories, made the following statement:

“The European Commission approval of ENFLONSIA marks a significant milestone in our journey to enable broad access and help reduce the burden of RSV disease on infants around the world. We are proud to bring ENFLONSIA to infants in Europe and look forward to equipping families and health care providers with this important new preventive option to help address this widespread and potentially serious disease.”

Merck & Co., Inc. (NYSE:MRK) operates as a global healthcare company. It develops and delivers treatments through prescription medicines, including biologics, vaccines, and animal health products. Its pharmaceutical segment focuses on human health drugs and vaccines.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Reddit Stocks That Will Skyrocket and 10 Fastest Growing Dividend Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.